- Home
- TVTX
as 01-17-2025 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.5B | IPO Year: | N/A |
| Target Price: | $24.58 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $20.33 | Next Earning Date: | 02-13-2025 |
| Revenue: | $203,447,000 | Revenue Growth: | 57.08% |
| Revenue Growth (this year): | 62.38% | Revenue Growth (next year): | 57.65% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Jan 3 '25 | Sell | $18.93 | 2,506 | $47,715.00 | 59,883 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Dec 26 '24 | Sell | $17.22 | 15,000 | $258,277.50 | 54,927 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Nov 25 '24 | Sell | $18.30 | 12,090 | $221,257.88 | 54,927 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Travere Therapeutics Provides Corporate Update and 2025 Outlook
GlobeNewswire
12 days ago
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
18 days ago
High Growth Tech Stocks in the United States to Watch
Simply Wall St.
24 days ago
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain
GlobeNewswire
2 months ago
Travere Therapeutics to Present at Upcoming Investor Conferences
Simply Wall St.
2 months ago
Exploring Three High Growth Tech Stocks in the United States
GlobeNewswire
2 months ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.